SARS-CoV-2 detection with CRISPR diagnostics
Lu Guo, Xuehan Sun, Xinge Wang, Chen Liang, Haiping Jiang, Qingqin Gao, Moyu Dai, Bin Qu, Sen Fang, Yihuan Mao, Yangcan Chen, Guihai Feng, Qi Gu, Ruiqi Rachel Wang, Qi Zhou & Wei Li
Cell Discovery volume 6, Article number: 34 (2020)
The novel coronavirus (CoV) disease termed COVID-19 (coronavirus disease-19) caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2)1 is causing a massive pandemic worldwide, threatening public health systems across the globe. During this ongoing COVID-19 outbreak, nucleic-acid detection has played an important role in early diagnosis2. To date, four protocols based on CRISPR for detecting SARS-CoV-2 have been published3,4,5,6. Using lateral flow protocols, RNA samples harboring more than 1 × 104–1 × 105 copies/mL (SHERLOCK) or 1 × 104 copies/mL (DETECTR) can be detected within 1 hour. In addition to these reported efforts, we have also established a SARS-CoV-2 detection protocol based on our previously reported platform—CDetection (Cas12b-mediated DNA detection)7. By combining sample treatment protocols and nucleic-acid amplification methods with CDetection, we have established an integrated viral nucleic-acid detection platform—CASdetec (CRISPR-assisted detection).
